https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):157-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):157-672007-03-01 00:00:002019-02-15 09:22:10Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):123-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / Curr Cancer Drug Targets 2007 Mar;7(2):123-52007-03-01 00:00:002019-02-15 09:22:11Oncolytic virus therapy–foreword
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / J Natl Compr Canc Netw 2007 Mar;5(3):345-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / J Natl Compr Canc Netw 2007 Mar;5(3):345-82007-03-01 00:00:002007-03-01 00:00:00Counterpoint: Hyperthermia with radiation therapy for chest wall recurrences
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-02-27 / Biomed. Pharmacother. 2007 Jul;61(6):306-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-02-27 / Biomed. Pharmacother. 2007 Jul;61(6):306-142007-02-27 00:00:002019-02-15 08:32:36Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-02-21 / Hum. Immunol. 2007 May;68(5):334-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-02-21 / Hum. Immunol. 2007 May;68(5):334-412007-02-21 00:00:002019-02-15 09:11:48alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-02-20 / Eur J Surg Oncol 2007 Dec;33(10):1191-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-02-20 / Eur J Surg Oncol 2007 Dec;33(10):1191-82007-02-20 00:00:002019-02-15 08:38:08A study of dendritic and endothelial cell interactions in colon cancer in a cell line and small mammal model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-02-09 / Cancer Res 2007 Feb;67(4):1842-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-02-09 / Cancer Res 2007 Feb;67(4):1842-522007-02-09 00:00:002023-03-07 13:12:37Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-02-07 / Cancer Immunol Immunother 2007 Sep;56(9):1485-99
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-02-07 / Cancer Immunol Immunother 2007 Sep;56(9):1485-992007-02-07 00:00:002023-03-07 13:13:36Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-02-01 / J. Intern. Med. 2007 Feb;261(2):123-31
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-02-01 / J. Intern. Med. 2007 Feb;261(2):123-312007-02-01 00:00:002019-02-15 09:15:13A dendritic cell-based vaccine for treating HIV infection: background and preliminary results
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-02-01 / Expert Opin Biol Ther 2007 Feb;7(2):221-32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-02-01 / Expert Opin Biol Ther 2007 Feb;7(2):221-322007-02-01 00:00:002019-02-15 09:17:00Dendritic cell vaccine strategies for renal cell carcinoma
